ARWR vs. ALNY
ARWR (Arrowhead Pharmaceuticals, Inc.) and ALNY (Alnylam Pharmaceuticals, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 10 years, ARWR returned 28.05%/yr vs 15.34%/yr for ALNY. At a 0.29 correlation, their price movements are largely independent.
Performance
ARWR vs. ALNY - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, ARWR achieves a 9.28% return, which is significantly higher than ALNY's -26.42% return. Over the past 10 years, ARWR has outperformed ALNY with an annualized return of 28.05%, while ALNY has yielded a comparatively lower 15.34% annualized return.
ARWR
- 1D
- 2.44%
- 1M
- -5.03%
- YTD
- 9.28%
- 6M
- 11.49%
- 1Y
- 336.79%
- 3Y*
- 26.25%
- 5Y*
- -0.96%
- 10Y*
- 28.05%
ALNY
- 1D
- 2.26%
- 1M
- -1.79%
- YTD
- -26.42%
- 6M
- -38.18%
- 1Y
- -3.68%
- 3Y*
- 14.74%
- 5Y*
- 14.98%
- 10Y*
- 15.34%
ARWR vs. ALNY - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
ARWR Arrowhead Pharmaceuticals, Inc. | 9.28% | 253.14% | -38.56% | -24.56% | -38.82% | -13.59% | 20.97% | 410.71% | 237.50% | 137.42% |
ALNY Alnylam Pharmaceuticals, Inc. | -26.42% | 68.99% | 22.94% | -19.46% | 40.14% | 30.48% | 12.85% | 57.96% | -42.61% | 239.34% |
Correlation
The correlation between ARWR and ALNY is 0.23, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.23 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.31 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.42 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.40 |
Correlation (All Time) Calculated using the full available price history since Jun 2, 2004 | 0.29 |
The correlation between ARWR and ALNY shifts across timeframes, from 0.23 (1 year) to 0.42 (5 years), reflecting how their relationship changes across market environments.
Fundamentals
ARWR:
$10.33B
ALNY:
$40.44B
ARWR:
-$2.16
ALNY:
$4.26
ARWR:
16.27
ALNY:
9.24
ARWR:
17.25
ALNY:
37.61
ARWR:
$622.01M
ALNY:
$4.29B
ARWR:
$529.27M
ALNY:
$2.51B
ARWR:
-$168.38M
ALNY:
$729.86M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
ARWR vs. ALNY — Risk / Return Rank
ARWR
ALNY
ARWR vs. ALNY - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Arrowhead Pharmaceuticals, Inc. (ARWR) and Alnylam Pharmaceuticals, Inc. (ALNY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| ARWR | ALNY | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 5.22 | -0.10 | +5.32 |
Sortino ratioReturn per unit of downside risk | 4.69 | 0.11 | +4.58 |
Omega ratioGain probability vs. loss probability | 1.59 | 1.01 | +0.58 |
Calmar ratioReturn relative to maximum drawdown | 13.77 | -0.09 | +13.86 |
Martin ratioReturn relative to average drawdown | 37.74 | -0.16 | +37.90 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| ARWR | ALNY | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 5.22 | -0.10 | +5.32 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.01 | 0.31 | -0.32 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.38 | 0.29 | +0.09 |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.01 | 0.32 | -0.33 |
Drawdowns
ARWR vs. ALNY - Drawdown Comparison
The maximum ARWR drawdown since its inception was -99.24%, which is greater than ALNY's maximum drawdown of -83.58%. Use the drawdown chart below to compare losses from any high point for ARWR and ALNY.
Loading charts...
Drawdown Indicators
| ARWR | ALNY | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.24% | -83.58% | -15.66% |
Max Drawdown (1Y)Largest decline over 1 year | -24.64% | -42.01% | +17.37% |
Max Drawdown (3Y)Largest decline over 3 years | -74.70% | -42.01% | -32.69% |
Max Drawdown (5Y)Largest decline over 5 years | -88.94% | -42.46% | -46.48% |
Max Drawdown (10Y)Largest decline over 10 years | -88.96% | -59.95% | -29.01% |
Current DrawdownCurrent decline from peak | -55.35% | -40.44% | -14.91% |
Average DrawdownAverage peak-to-trough decline | -81.24% | -30.59% | -50.65% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 8.97% | 22.83% | -13.86% |
Volatility
ARWR vs. ALNY - Volatility Comparison
Arrowhead Pharmaceuticals, Inc. (ARWR) has a higher volatility of 17.17% compared to Alnylam Pharmaceuticals, Inc. (ALNY) at 8.81%. This indicates that ARWR's price experiences larger fluctuations and is considered to be riskier than ALNY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| ARWR | ALNY | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 17.17% | 8.81% | +8.36% |
Volatility (6M)Calculated over the trailing 6-month period | 39.41% | 26.06% | +13.35% |
Volatility (1Y)Calculated over the trailing 1-year period | 65.03% | 36.52% | +28.51% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 65.03% | 48.85% | +16.18% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 74.14% | 53.68% | +20.46% |
Dividends
ARWR vs. ALNY - Dividend Comparison
Neither ARWR nor ALNY has paid dividends to shareholders.
Financials
ARWR vs. ALNY - Financials Comparison
This section allows you to compare key financial metrics between Arrowhead Pharmaceuticals, Inc. and Alnylam Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
ARWR and ALNY have a correlation of 0.23, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
ARWR has higher volatility (17.17%) compared to ALNY (8.81%). In terms of maximum drawdown, ARWR dropped -99.24% vs ALNY's -83.58%.
ARWR currently has the higher Sharpe Ratio (5.22 vs -0.10), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for ARWR and ALNY
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer